The global hyperhidrosis treatment market size is anticipated to register a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of secondary hyperhidrosis condition.
Hyperhidrosis is a chronic disorder of excessive sweating beyond thermoregulatory requirements and environmental circumstances. It normally develops in childhood and teenage years affecting patients for longer period.
In many cases of hyperhidrosis, unnecessary sweating occurs majorly in armpits, soles, face, and palms. It also affects abdomen, inguinal regions, chest, back, and lower limb. There are various symptoms of hyperhidrosis which causes fungal and bacterial infections. Hyperhidrosis is caused due to several reasons heart disease, obesity, anxiety disorder, and infectious diseases such as tuberculosis, malaria.
Growing incidences of secondary hyperhidrosis are related to alcohol habits, sedentary lifestyle, and unhealthy diet which causes several diseased conditions such as anxiety, hypoglycemia, and hyperthyroidism. These diseases sometimes have disturbing psychological effects such as social anxiety and embarrassment. It also emotionally affects a person. Patients having hyperhidrosis are prone to skin diseases.
Based on study published in Journal of the American Academy of Dermatology (JAAD), in 2017 around 3% of the US population were suffered from hyperhidrosis.
Due to rising incidences of this disease, major players are investing huge amount in hyperhidrosis treatment market. But, results of treatments are only for certain period of time because of which patient have to repeat the treatments. However, pipeline of novel hyperhidrosis treatment along with increasing investment in research are anticipated to aids the market expansion.
Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of hyperhidrosis is major factor responsible for driving the market growth over the forecast period.
- Rising awareness about treatment methods and medications among people and growing demand of treatment are projected to fuel the market expansion.
- Increasing investment in research and development and availability of medication and treatments are expected to boost the expansion of the market in the coming years.
- Huge consumption of alcohol, changing lifestyle, and non-nutritive diet are anticipated to propel the market expansion.
- Increasing demand of treatments and emergence of novel treatments and medications are expected to drive the market growth over the forecast period.
- High cost of treatment is major factor responsible for hampering the market expansion over the forecast period.
Scope of Hyperhidrosis Treatment Market Report
The report on the global hyperhidrosis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Hyperhidrosis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018–2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Types (Primary Focal and Secondary Generalized), Treatments (Topical Treatment, Botulinum Toxin A, Iontophoresis, Surgical Treatment, and Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Allergan; Brickell Biotech, Inc.; Miramar Labs, Inc.; Dermira, Inc.; GlaxoSmithKline plc.; Revance Therapeutics, Inc.; Ulthera, Inc.; Dr. August Wolff GmbH; and TheraVida?
|
Hyperhidrosis Treatment Market Segment Insights
Secondary generalized segment is expected to expand at a rapid pace
In terms of types, the hyperhidrosis treatment market is bifurcated into primary focal and secondary generalized.
The primary focal segment is expected to account for a key share of the market during the forecast period owing to availability of advanced therapies in different sections includes topical and surgical. Primary focal hyperhidrosis affects equally to both men and women. Botox developed by Allergen was the only approves treatment on primary focal hyperhidrosis.
On the other hand, the secondary generalized segment is anticipated to expand at a rapid pace during the forecast period. It is most commonly found disease type. It caused due to side effects of medicines. Furthermore, any medical condition can cause secondary generalized hyperhidrosis. Rising prevalence of anxiety and depression around the world is expected to fuel the segment growth.
Topical treatment segment is projected to hold a key market share
On the basis of treatments, the market is segmented into topical treatment, botulinum toxin A, iontophoresis, surgical treatment, and others.
The topical treatment segment is expected to hold a key share of the market in the coming years. This treatment is a primary treatment for many cases of hyperhidrosis. Also, it includes include aluminum chloride, anticholinergics and local anesthetics, and astringent agents for the treatment of hyperhidrosis. In mild cases the topical treatment using antiperspirant solutions as Driclor (aluminium chloride hexahydrate) and corticosteroid creams are suggested.
However, the botulinum toxin A segment is anticipated to expand at a rapid pace during the forecast period. The botulinum toxin A is recommended for first or second line of treatment as it is safe and effective treatment option. This therapy is generally used in all affected areas of the body. Majorly for treating hyperhidrosis of soles and palms the iontophoresis treatment is recommended. Oral anticholinergics are recommended when other treatments fail.
Online pharmacy segment is expected to expand at a rapid pace
Based on distribution channels, the hyperhidrosis treatment market is divided into hospital pharmacy, retail pharmacy, and online pharmacy.
The retail pharmacy segment is expected to account for a key share of the market in the coming years owing to its easy availability and accessibility.
However, the online pharmacy segment is anticipated to expand at a rapid pace during the forecast period due to growing awareness among people. People are choosing online pharmacies due to beneficial offers such as availability of drugs, price discounts, and home delivery services.
North America is anticipated to dominate the market
On the basis of regions, the hyperhidrosis treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to the increasing incidences of secondary hyperhidrosis. The US has huge number of patients suffering from hyperhidrosis along with favorable reimbursement policies are projected to boost the regional market growth.
Furthermore, improved government and NGO initiatives, increasing awareness about advantages of medications, and availability of research funds are expected to fuel the market growth.
Segments
The global hyperhidrosis treatment market has been segmented on the basis of
Types
- Primary Focal
- Secondary Generalized
Treatments
- Topical Treatment
- Botulinum Toxin A
- Iontophoresis
- Surgical Treatment
- Others
Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the hyperhidrosis treatment market are Allergan; Brickell Biotech, Inc.; Miramar Labs, Inc.; Dermira, Inc.; GlaxoSmithKline plc.; Revance Therapeutics, Inc.; Ulthera, Inc.; Dr. August Wolff GmbH; and TheraVida.
Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
